DOI : 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Issue 01 · Volume 59 · January 2021 DOI: 10.1055/s-011-50135

Deutsche Arbeitsgemeinschaft zum Studium der Leber
37. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
Münster, 29.-30.01.2021

Kongresspräsident: Prof. Dr. Andreas Pascher
Abstracts (HTML) Abstracts (PDF) List of Authors
4.4
Deutschmann, K; Reich, M; Lang, A; Piekorz, R; Gertzen, C; Gohlke, H; Häussinger, D; Luedde, T; Keitel, V: Role of the bile acid receptor TGR5 (GPBAR1) in cholangiocarcinoma (CCA) progression and tumor spread
4.5
Piche, J; Otto, T; Mohs, A; Woitok, MM; Trautwein, C: ACSL4 and its tumor protective role in chronic liver disease
4.6
Taube, M; Stein, S; Höh, B; Glaser, F; Poch, T; Weidemann, S; Longerich, T; Ittrich, H; Schwinge, D; Schramm, C: Interleukin-17 enhances the risk for tumor development in chronic sclerosing cholangitis
4.7
Pellegrino, R; Ticconi, F; Castoldi, M; Skawran, B; Schirmacher, P; Costa, I; Longerich, T: LINC00152 regulates KLC2 via sponging of miR143/KLC2 thereby promoting proliferation of human liver cancer cells
4.8
Nischalke, HD; Fischer, J; Krämer, B; Langhans, B; Goeser, F; Soyka, M; Stickel, F; Spengler, U; Nattermann, J; Strassburg, C; Berg, T; Lutz, P: A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis
4.9
Gehrke, N; Straub, BK; Wörns, MA; Galle, PR; Schattenberg, JM: Inhibition of the IL-1R1 pathway in hepatocytes reduces tumor growth in a mouse model of NAFLD-associated HCC
4.10
Wesener, M; Merker, S; Helm, B; Thiess, L; Klingmüller, U; Ruppert, T; Schirmacher, P; Breuhahn, K; Weiler, S: The common and mutual exclusive interactome of the oncogenes YAP and TAZ in liver cancer
4.11
Fritzsche, S; Fraas, A; Goeppert, B; Albrecht, T; Loeffler, M; Schirmacher, P; Rössler, S: Implications of NOTCH3 expression and signaling for cholangiocarcinogenesis
4.12
Goeppert, B; Stichel, D; Toth, R; Fritzsche, S; Loeffler, M; Schlitter, AM; Neumann, O; Assenov, Y; Vogel, MN; Mehrabi, A; Hoffmann, K; Köhler, B; Springfeld, C; Weichenhan, D; Plass, C; Esposito, I; Schirmacher, P; von Deimling, A; Rössler, S: Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal cholangiocarcinogenesis
4.13
Castven, D; Czauderna, C; Becker, D; Pereira, S; Breuhahn, K; Schmitt, J; Hajduk, J; Keggenhoff, F; Wörns, MA; Thorgeirsson, SS; Grimminger, P; Lang, H; Galle, PR; Marquardt, JU: Targeting cancer stem cells and YAP signaling as an effective approach to overcome sorafenib resistance in HCC
4.14
Tang, Y; Thiess, L; Weiler, SME; Schirmacher, P; Breuhahn, K: Overexpression of CTNNA1 supports nuclear enrichment of the oncogene YAP in hepatocarcinogenesis
4.15
Wehling, L; Keegan, L; Schmitt, J; Sahle, S; Schirmacher, P; Kummer, U; Breuhahn, K: Mathematical modeling of YAP and TAZ nuclear/cytoplasmic shuttling in liver cancer cells
4.16
Hajduk, J; Becker, D; Heinrich, S; Czauderna, C; Castven, D; Straub, B; Grimminger, P; Galle, P; Weinmann, A; Marquardt, J: Dissecting molecular drivers of sorafenib resistance in HCC: integrative genomic analyses of poor and good responders
4.17
Sugiyanto, RN; Truckenmueller, F; Goeppert, B; Pusch, S; Mehrabi, A; Schirmacher, P; Ori, A; Roessler, S: Deciphering the role of FHL1 as tumor suppressor in gallbladder cancer
4.18
Spiliotis, A; Gäbelein, G; Holländer, S; Scherber, PR; Patel, B; Glanemann, M: Radiofrequency ablation compared with microwave ablation for the treatment of liver cancer: a meta-analysis.
4.19
Ganjian, N; Abadi, Z; Trompak, O; Geffers, R; Zender, L; Pellegrino, R; Longerich, T: Dissecting the molecular interplay between tumor cells and –stroma in primary liver cancer
4.20
Fischer, J; Long, S; Koukoulioti, E; Müller, T; Fueloep, B; Heyne, R; Eslam, M; George, J; Finkelmeier, F; Waidmann, O; van Bömmel, F; Berg, T: Genetic variants of interleukin 1 beta are associated with viral hepatitis-related HCC in Caucasian patients
4.21
Schemmel, N; Fleischmann-Mundt, B; Öhler, LA; Wedemeyer, H; Lauer, UM; Wirth, TC; Kühnel, F: Establishment of a transgenic, single-nodule model of liver cancer in a fibrotic background
4.22
Michalski, M; Wiesner, O; Müller-Schilling, M; Gülow, K: Dimethyl fumarate (DMF) inhibits proliferation and induce specific cell death in hepatocellular carcinoma (HCC)
4.23
Araos, J; Cai, C; Gaitantzi, H; Itzel, T; Teufel, A; Dooley, S; Hawinkels, L; Birgin, E; Rahbari, N; Ebert, M; Breitkopf-Heinlein, K: Upcoming expression of ALK1 in HCC determines the switch from tumour-suppressive to tumour-promoting BMP-9 signalling
4.24
Freese, K; Sommer, J; Seitz, T; Lee, SML; Thasler, WE; Bosserhoff, A; Hellerbrand, C: Expression and function of histone deacetylase 7 in hepatocellular carcinoma
4.25
Brandes, L; Aschenbrenner, E; Pollinger, K; Gülow, K; Kunst, C; Müller-Schilling, M: Combining targeted therapies with HDAC inhibitors to tackle the p53 signaling pathway in hepatocellular carcinoma
4.26
Gülow, K; Ostheim, E; Müller-Schilling, M: The Alpha-1-Fetoprotein (AFP) – A novel target gene for p63
4.27
Ridder, D; Schindeldecker, M; Berndt, K; Urbansky, L; Witzel, H; Weinmann, A; Heinrich, S; Roth, W; Straub, B: Key enzymes in pyrimidine synthesis, CAD and CPS1, predict prognosis in hepatocellular carcinoma
4.28
Castoldi, M; Vucur, M; Roderburg, C; Loosen, S; Luedde, T: Functional relevance of the tumor suppressor activity of mir-107 in liver cancer
4.29
Daza, J; Itzel, T; Ebert, MP; Teufel, A: Survival analysis of the most frequent Single Nucleotide Variants in Hepatocellular Carcinoma
4.30
Glisic, L.; Kühn, N; Aschenbrenner, E; Pollinger, K; Neufurth, M; Müller, W; Armbruster, FP; Kunst, C; Gülow, K; Müller-Schilling, M; Müller, W: Einfluss von polyP-Substraten auf das Wachstumsverhalten des HCCs als Grundlage für ein innovatieves Tumormodell